Wat is de prijs voor Gamida Cell Ltd. (GMDA)

Het prijs van Gamida Cell Ltd. (GMDA) is $0.0327

Wat is de marktkapitalisatie voor Gamida Cell Ltd. (GMDA)

Marktkapitalisatie voorGamida Cell Ltd. (GMDA) is $4.34M

Gamida Cell Ltd. (GMDA) K/B-verhouding

Gamida Cell Ltd. operates as a clinical-stage biopharmaceutical firm, dedicated to pioneering cell therapies aimed at eradicating blood cancers and other severe hematological conditions. The company's leading investigational product, omidubicel—a specialized cell therapy—has successfully concluded its Phase III clinical evaluation for individuals afflicted with high-risk hematologic malignancies. Furthermore, it is currently undergoing Phase I/II trials for patients suffering from severe aplastic anemia. Another significant therapeutic candidate, GDA-201, an immunotherapy harnessing natural killer cells, is progressing through Phase I/II studies to address relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Beyond these, Gamida Cell is actively advancing a broader natural killer (NK) cell pipeline, which includes GDA-301, GDA-401, GDA-501, and GDA-601, with the ambition of treating both hematologic cancers and solid tumors. Founded in 1998, the company maintains its corporate headquarters in Jerusalem, Israel.

Jaar	P/B-ratio	Wijzigen
Niet genoeg gegevens voor de verstrekte datums.

Jaar

P/B-ratio

Wijzigen

Niet genoeg gegevens voor de verstrekte datums.

Bedrijf	P/B-ratio	Verschil in P/B-ratio	Land
Vertex Pharmaceuticals Incorporated VRTX.US	6.3419	-	US
Argenx SE ARGX.US	6.2413	-	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	3.4612	-	BE

Bedrijf

P/B-ratio

Verschil in P/B-ratio

Land